Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5112 - Long-term results of chemoradiotherapy for stage III nasopharyngeal carcinoma patients and risk grouping by pretreatment EBV viral load

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Surgical Oncology;  Radiation Oncology;  Head and Neck Cancers

Presenters

Po-Ju Lin

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

P. Lin1, W. Wang2, Y.C. Liu3, J. Lin3

Author affiliations

  • 1 Department Of Radiation Oncology, Tungs' Taichung MetroHarbor Hospital, 407 - Taichung/TW
  • 2 Department Of Nursing, Hung Kuang University, 40705 - Taichung/TW
  • 3 Radiotion_oncology, Taichung Veterans General Hospital, 40705 - Taichung/TW
More

Resources

Abstract 5112

Background

No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The aim of this study is to investigate the long-term clinical outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.

Methods

A total of 356 previously untreated, pathologically-proven NPC patients with stage III disease and available pretreatment plasma EBV DNA data were enrolled in this retrospective study. Initial definitive treatment consisted of concurrent chemoradiotherapy or induction chemotherapy plus radiotherapy. Eighty-four of 356 (23.6%) patients also received post-RT adjuvant chemotherapy. Patients with pretreatment EBV DNA > 1000 copies/mL were defined as a high-risk subgroup (n = 106) and the remaining patients as a low-risk subgroup (n = 250).

Results

After a median follow-up of 90 months, there were 66 recurrences (18.5%) and 57 deaths (16.0%). The 5-year overall survival (OS), progression-free survival (PFS), distant metastasis failure-free survival (DMFFS), and locoregional failure-free survival (LRFFS) for all 356 patients were 88.4%, 83.9%, 90.5%, and 90.5%, respectively. Thirty-five of 105 (33.0%) high-risk patients developed tumor relapse later, whereas only 12.4% (31/250) low-risk patients had tumor relapse (P 

Conclusions

Long-term treatment results for Stage III NPC patients were good. Risk grouping identified a subgroup of patients with high pretreatment EBV DNA had a significantly higher relapse rates and worse survivals. Future trial should strengthen treatment intensity for these high-risk patients.

Clinical trial identification

Legal entity responsible for the study

Taichung Veterans General Hospital

Funding

Taichung Veterans General Hospital

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.